DataMeds AI Launches $10.0M At-The-Market Program With Dawson James
MEDS sits 29% above its 52-week low of $0.553.
Summary
DataMeds AI signed a $10,003,649 at-the-market sales agreement with Dawson James at a 3.0% commission. No shares have been sold yet, but the program gives a going-concern company a way to raise cash by selling stock into the market over time.
Updates
· SEC 424B5 — The ATM prospectus supplement sets the offering at up to $10,003,649, or up to 13,518,445 shares at $0.74, with Dawson James paid a 3.0% commission.
- Book Value and Dilution — Historical net tangible book value was $(28.9) million, or $(6.10) per share, on 4,730,148 shares outstanding at September 30, 2026. Pro forma would be $(29.3) million, or $(5.13) per share, and as adjusted $(19.8) million, or $(1.03) per share, with $4.11 per share increase to existing stockholders and $1.77 dilution to new investors.
- Share Count — Up to 19,243,302 shares outstanding after the offering, assuming sale of up to 13,518,445 shares at $0.74 per share.
- Use of Proceeds — Net proceeds intended for debt repayment, working capital and other general corporate purposes, and pending use invested in short-term, investment-grade, interest-bearing instruments and government securities.
- Expenses — Company reimburses Sales Agent's legal counsel fees up to a maximum of $75,000, plus legal counsel costs, fees and expenses not to exceed $10,000 per fiscal year.
- Termination and Suspension — Either party may terminate upon ten days' prior notice, subject to other conditions; either party may suspend the offering upon proper notice; the offering terminates automatically upon sale of all shares.
- Sales Mechanics — Sales Agent acts on commercially reasonable efforts without obligation to sell any specific amount, using at the market offering methods under Rule 415(a)(4). Company may set a minimum price; settlement occurs the first business day after sales, with no escrow, through The Depository Trust Company.
- Regulatory Limits — Company eligible under General Instruction I.B.6 of Form S-3 with no securities sold under it in the prior 12-calendar month period. Public primary offerings capped at one-third of public float in any 12-month period while float is below $75.0 million; Sales Agent will not engage in market making under Regulation M.
- Reporting and Indemnification — Company will report at least quarterly the number of shares sold and net proceeds. Sales Agent deemed an underwriter, with indemnification and contribution for certain Securities Act and Exchange Act liabilities.
- Counsel and Filing — Sheppard, Mullin, Richter & Hampton LLP passed on validity; Nelson Mullins Riley & Scarborough LLP is Sales Agent's counsel. Sales Agreement filed as an exhibit to a Current Report on Form 8-K dated November 16, 2026.
All 25 details
- Company reimburses Sales Agent's legal counsel fees up to a maximum of $75,000, plus legal counsel costs, fees and expenses not to exceed $10,000 per fiscal year.
- Net proceeds intended for debt repayment, working capital and other general corporate purposes.
- Sales Agreement may be terminated upon proper notice to the other party and subject to other conditions.
- Offering terminates automatically upon sale of all shares subject to the Sales Agreement.
- Pro forma as adjusted net tangible book value at September 30, 2026 would have been $(19.8) million, or $(1.03) per share.
- Immediate increase of $4.11 per share in pro forma as adjusted net tangible book value to existing stockholders; immediate dilution of $1.77 per share to new investors.
- Settlement occurs on the first business day following the date sales are made, or another agreed date; no arrangement for funds in escrow, trust or similar arrangement.
- Sales Agent deemed an underwriter under the Securities Act; Company agreed to provide indemnification and contribution to Sales Agent for certain liabilities, including Securities Act and Exchange Act liabilities.
- Sales Agreement may be terminated by either party upon ten days' prior notice.
- Pro forma net tangible book value at September 30, 2026 would have been $(29.3) million, or $(5.13) per share.
- Up to 19,243,302 shares outstanding after offering, assuming sale of up to 13,518,445 shares at $0.74 per share.
- Validity of shares passed upon by Sheppard, Mullin, Richter & Hampton LLP, New York, New York; Nelson Mullins Riley & Scarborough LLP, Raleigh, NC, counsel for the Sales Agent.
- Transfer agent and registrar is Colonial Stock Transfer Company, Inc.
- Company eligible under General Instruction I.B.6 of Form S-3; no securities sold under it in prior 12-calendar month period ending on and including the prospectus supplement date, excluding this offering.
- In no event will company sell securities in a public primary offering exceeding one-third of public float in any 12-month period while public float remains below $75.0 million.
- Company will report at least quarterly the number of shares sold and net proceeds under the Sales Agreement.
- Sales Agent will not engage in market making activities involving common stock while the offering is ongoing under Regulation M.
- Pending use, net proceeds invested in short-term, investment-grade, interest-bearing instruments and government securities.
- Sales Agent may sell shares by methods deemed an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933.
- Company may instruct the Sales Agent not to sell common stock below a designated price.
- Company or Sales Agent may suspend the offering upon proper notice to the other party.
- Sales settled through the facilities of The Depository Trust Company or by such other means as the Company and Sales Agent may agree.
- Sales Agent is not required to sell any specific amount of securities but acts as sales agent using commercially reasonable efforts.
- Sales Agreement filed as an exhibit to a Current Report on Form 8-K dated November 16, 2026.
- Historical net tangible book value of $(28.9) million, or $(6.10) per share of common stock, based on 4,730,148 shares of common stock outstanding at September 30, 2026.
Key Events · Financing and Capital Events · MEDS
-
New $10.0M ATM Sales Agreement
On November 16, 2026, DataMeds AI entered an at-the-market sales agreement with Dawson James Securities under which it may offer and sell up to $10,003,649 of common stock from time to time.
-
3.0% Agent Commission
Dawson James receives a fixed 3.0% of gross proceeds on shares sold, plus reimbursement of certain expenses; the company is not obligated to sell any shares.
-
Shelf Registration Underpins Program
Sales are made under the Form S-3 shelf (File No. 333-295078) filed April 15, 2026 and declared effective May 7, 2026, via a prospectus supplement dated November 16, 2026.
-
Cash Need Against Going-Concern Doubt
The program follows the November 13, 2026 10-Q, which reported $3.4M of operating losses and going-concern doubt — an ATM lets the company raise cash without a single priced offering.
Analysis · MEDS · Trade & Services
The authorization to drip-feed up to $10,003,649 of new stock into the market through Dawson James at a 3.0% commission is what matters here. No shares have been sold yet — this is an authorization, not a completed raise — but the size is significant: the company's entire market value is only a few million dollars, so fully using this shelf would be massively dilutive to existing holders. Timing is the real story. The move comes three days after the 10-Q disclosed going-concern doubt and $3.4M of operating losses, and it follows a string of share-based deals (Helomics, REBOOT, the MIPA settlement) that have already expanded the share count. An ATM gives management a cash tap without a priced offering, but it also means a steady supply of new shares can hit the Nasdaq market whenever the stock trades above management's minimum price.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MEDS was trading at $0.71 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.55 to $35.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.